Sign In
Buy SLP
$16.17
-0.600 (-3.58%)
At Close: Jun 03, 2026
Simulations Plus Releases DILIsym® 11
07:50am, Thursday, 15'th May 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and i
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
07:50am, Monday, 21'st Apr 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and i
Simulations Plus: Benefiting From FDA Modernization And AI
08:30am, Wednesday, 16'th Apr 2025
Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, incl
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
10:44am, Friday, 11'th Apr 2025
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Simulations Plus: I See Promising Growth, But I'm Staying Neutral
11:24am, Friday, 04'th Apr 2025
Simulations Plus, Inc. excels with its AI-driven biosimulation platforms, aiding drug development, but faces challenges with margin erosion and cash flow pressures. Despite strong revenue growth and p
SLP's Q2 Earnings Top, Sales Up Y/Y Despite Industry Headwinds
09:45am, Friday, 04'th Apr 2025
Simulations Plus' fiscal Q2 2025 performance gains from its strong software solutions and services portfolio amid limited customer funding.
Simulations Plus, Inc. (SLP) Q2 2025 Earnings Call Transcript
08:44pm, Thursday, 03'rd Apr 2025
Simulations Plus, Inc. (NASDAQ:SLP ) Q2 2025 Earnings Conference Call April 3, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & CO
Simulations Plus (SLP) Tops Q2 Earnings and Revenue Estimates
06:21pm, Thursday, 03'rd Apr 2025
Simulations Plus (SLP) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago.
Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results
04:05pm, Thursday, 03'rd Apr 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and i
Simulations Plus Gears Up for Q2 Earnings: What's in the Offing?
10:05am, Tuesday, 01'st Apr 2025
SLP's fiscal Q2 2025 performance is likely to have benefited from continued momentum across its Software and Services segments amid budget constraints.
Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date
07:00am, Thursday, 20'th Mar 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled perfor
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum
07:00am, Monday, 10'th Mar 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled perfor
Simulations Plus to Participate in Upcoming Healthcare Investor Conferences
07:30am, Tuesday, 04'th Feb 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled perfor
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
07:50am, Wednesday, 22'nd Jan 2025
RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions,
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
07:13pm, Monday, 13'th Jan 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharma industry through support of the development of a majority of the drugs approved by the U.S. FDA in 2024.
